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INTRODUCTION
Acute kidney injury (AKI) is a common clinical problem in criti-
cally ill patients.1-3 The prevalence of AKI among intensive care 
unit (ICU) patients varies between 30–50%, with an attributed 
mortality rate varying between 28–90%.1-4 Sepsis is a leading 
cause of AKI in clinical practice.5 It is estimated that more than 
20% of septic patients may show some degree of AKI, and the 
mortality rate of this subgroup reaches up to 35%.6 Tissue hypo-
perfusion is the main reason for the development of sepsis-in-
duced AKI.
Serum creatinine has typically been used for AKI diagnosis. 
However, the release of creatinine varies with age, gender, diet, 
muscle mass, drugs, hepatic dysfunction, and immobility.7-10 
Furthermore, serum creatinine levels become abnormal with 
a more than 50% reduction in the glomerular filtration rate 
(GFR).7-10 Therefore, there is a delay between injury and the 
subsequent rise in serum creatinine, indicating that it might 
require up to 48 h before a sufficient increase becomes detect-
able.7-10 Thus, the diagnosis of AKI and prognostic prediction in 
patients with AKI are important in routine ICU practice. If AKI 
is diagnosed as early as possible, preventive measures, such as 
avoiding nephrotoxic drugs and radiocontrast exposure, can 
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be undertaken. Therefore, early diagnosis can help to prevent 
the development and progression of acute renal dysfunction.
Serum cystatin C is a new biomarker that has been used in 
recent years to diagnose AKI as early as possible.11 Cystatin C is 
a nonglycosylated 13-kDa protein and is a member of the cys-
tatin superfamily of cysteine protease inhibitors. It is regularly 
produced by all nucleated cells, freely filtered at the glomeru-
lus, mostly reabsorbed at the proximal tubule via megalin-me-
diated endocytosis, and finally catabolized. Cystatin C is well 
known as a good predictor of AKI development in critically ill 
patients. Compared to serum creatinine, the level of serum 
cystatin C is not significantly affected by age, gender, race, or 
muscle mass.2
The use of serum cystatin C as an early detector of AKI has 
been evaluated in several studies.7-10 However, the role of serum 
cystatin C for the prediction of renal function recovery has not 
been well established. Therefore, the aim of this study was to 
assess the value of serum cystatin C for the early detection and 
prediction of renal function recovery in patients with sepsis.
MATERIALS AND METHODS
Study population
This study was a prospective cohort study, performed in a med-
ical ICU of a 2500-bed tertiary university hospital in South Ko-
rea. The medical ICU is a 30-bed closed unit that is managed by 
certified ICU specialists who only care for ICU patients. We 
consecutively enrolled patients with sepsis admitted to the ICU 
for 5 months. Patients were excluded if they were <16 years of 
age or with a known history of chronic renal disease.
Sepsis was defined as the identification of infection site, in 
addition to two or more of the following systemic inflammatory 
response syndrome criteria: 1) body temperature less than 36°C 
(96.8°F) or greater than 38°C (100.4°F); 2) heart rate greater than 
90 beats/min; 3) tachypnea of greater than 20 breaths/min or 
arterial partial pressure of carbon dioxide less than 4.3 kPa (32 
mm Hg); and 4) white blood cell count of less than 4000 cells/
mm3 (4×109 cells/L) or greater than 12000 cells/mm3 (12×109 
cells/L).12 Septic shock was defined as sepsis-induced hypoten-
sion persisting despite adequate fluid resuscitation.13 All eligible 
patients in this study were managed according to the guidelines 
of the “Surviving sepsis campaign: international guidelines for 
management of severe sepsis and septic shock: 2008”.13
AKI was defined according to the Risk, Injury, Failure, Loss 
of kidney function, and End-stage kidney disease criteria.14 The 
classification system includes separate criteria for creatinine 
[risk: 1.5-fold increase in serum creatinine level or >25% de-
crease in GFR; injury: two-fold increase in serum creatinine 
level or >50% decrease in GFR; and failure: three-fold increase 
in serum creatinine level or 75% decrease in GFR or increase in 
serum creatinine level to ≥4 mg/dL (≥354 μmol/L) with an acute 
increase ≥0.5 mg/dL (≥44 μmol/L)] and urine output (risk: urine 
output <0.5 mL·kg-1·h-1×6 h; injury: urine output <0.5 mL·kg-1 
·h-1×12 h; and failure: urine output <0.5 mL·kg-1·h-1×24 h or an-
uria×12 h).14 When AKI occurred within 3 days after ICU ad-
mission, patients were classified as AKI group. Recovery of AKI 
was defined as a post-AKI serum creatinine level within 25% of 
the baseline (pre-hospitalization value) and independence 
from renal replacement therapy (RRT).
For each patient, age, gender, body mass index (BMI), co-
morbidity, infection strain, administration of vasoactive drugs, 
length of ICU stay, and 28-day mortality were recorded. In ad-
dition, Acute Physiology and Chronic Health Evaluation II 
(APACHE II) scores, Sequential Organ Failure Assessment 
(SOFA) scores, and laboratory data, including cystatin C and 
serum creatinine levels, were collected on days 0 (ICU admis-
sion), 1, 3, and 7. In this study, we defined “recovery” as recov-
ery of AKI within 1 month after ICU admission; otherwise, the 
patients were classified in the “non-recovery” group.
Blood sampling and assays
Blood samples were obtained by an indwelling arterial catheter 
or venous puncture as soon as possible after the patient was 
admitted to the ICU. Follow-up blood samples from days 1, 3, 
and 7 were obtained at a fixed time (5 AM) for all eligible pa-
tients. The levels of creatinine and cystatin C were measured 
using commercial kits with an automated analyzer (Hitachi 
7600-200-DDP, Hitachi Ltd., Tokyo, Japan).
Statistical analysis
Continuous variables were compared using the Student t-test 
or Mann-Whitney U test, depending on the distribution, and 
are presented as mean±standard deviation. Categorical vari-
ables were compared using Pearson’s chi-squared test or Fish-
er’s exact test and are presented as absolute frequency and per-
centages.15 The changes in serum levels of cystatin C over time 
between groups were compared using linear mixed model 
analysis after adjusting for age, sex, and BMI. For logistic regres-
sion analysis, univariate analysis was performed first, and 
p<0.05 was considered statistically significant.16,17 Additionally, 
multivariate analysis was performed using the forward stepwise 
data selection method.16,17 Cut-off values of 0.05 and 0.1 were 
applied to either enter or remove covariates into or from the fi-
nal model. The effect of age, gender, and SOFA score was evalu-
ated using Cox proportional-hazard models, in which adjusted 
p-values<0.05 were considered statistically significant. Hazard 
ratios and 95% confidence intervals (CIs) were calculated. All 
statistical analyses were carried out using SPSS version 20 (SPSS 
Inc., Chicago, IL, USA).
Ethics statement
The study protocol was reviewed and approved by the Institu-
tional Review Board of Yonsei University Health Service, Sev-
erance Hospital (IRB approval number: No. 4-2008-0099).
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RESULTS
A total of 179 patients with sepsis were admitted to the ICU of a 
university-affiliated hospital in Korea. Among them, 17 patients 
who had a history of chronic kidney disease were excluded. 
Among the remaining 162 patients, AKI developed in 113 pa-
tients (43 of risk, 40 of injury, and 30 of failure). Thirty of these 
AKI patients were excluded because they died within 3 days af-
ter ICU admission (n=18) or the serum cystatin C measurement 
was not available after day 3 (n=12) (Fig. 1).
The baseline demographic and clinical characteristics at 
admission to the ICU (day 0) of the 162 included patients are 
shown in Table 1. Age and gender were similar between the 
non-AKI and AKI groups. The APACHE II scores and SOFA 
scores were significantly higher in the AKI group than in the 
non-AKI group (p=0.004 and p<0.001, respectively). Diabetes 
mellitus and hypertension were more frequent in the AKI 
group.
Levels of blood urea nitrogen, creatinine, and cystatin C were 
significantly higher in the AKI group (all p<0.001). The changes 
in serum creatinine, GFR, and cystatin C levels of the AKI and 
non-AKI groups over time are shown in Fig. 2. Similarly to the 
Table 1. Baseline Characteristics of AKI and Non-AKI Patients at Day 0 of ICU Admission (n=162)
Variables Non-AKI (n=49) AKI (n=113) p value
Age, yrs 60.6±16.5 61.9±15.4 0.636
Male (%) 31 (63.3) 69 (61.1) 0.791
BMI, kg/m2 21.8±3.9 23.8±3.8 0.004
Length of ICU stay, days 19.8±20.5 14.7±16.2 0.095
Disease severity
Septic shock (%) 43 (87.8) 96 (85.0) 0.639
APACHE II score 17.4±4.7 20.1±5.6 0.004
SOFA score 6.4±3.2 8.8±3.6 <0.001
28-day mortality (%) 26 (53.1) 57 (50.4) 0.759
Underlying diseases (%)
Diabetes mellitus 4 (8.2) 40 (35.4) <0.001
Chronic lung disease* 16 (32.7) 13 (11.5) 0.001
Hypertension 13 (26.5) 54 (47.8) 0.015
Heart failure 5 (10.2) 14 (12.4) 0.691
Coronary artery disease 7 (14.3) 9 (8.0) 0.215
Chronic liver disease 6 (12.2) 20 (17.7) 0.385
Clinical parameters
Hemoglobin, g/dL 10.2±1.9 9.7±2.2 0.115
Platelets, 103/mm3 221.4±180.6 172.3±154.0 0.272
Blood urea nitrogen, mg/dL 14.6±7.9 39.4±24.8 <0.001
Creatine, mg/dL 0.99±1.9 2.3±1.9 <0.001
eGFR, mL/min/1.73 m2 120.6±43.4 44.0±25.0 <0.001
Cystatin C, mg/dL 0.7±0.3 1.9±1.3 <0.001
IGF-1, μg/dL 72.5±48.0 68.0±55.5 0.614
CRP, mg/dL 18.8±11.0 17.0±12.7 0.350
AKI, acute kidney injury; BMI, body mass index; ICU, intensive care unit; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ 
Failure Assessment; eGFR, estimated glomerular filtration rate; IGF-1, insulin-like glomerular factor-1; CRP, C-reactive protein.
*Chronic lung disease includes asthma, chronic obstructive pulmonary disease, and structural lung diseases, such as bronchiectasis and interstitial lung disease.
Non-AKI (n=49) AKI (n=113)
AKI (n=83)
Recovery (n=34) Non-recovery (n=49)
Chronic kidney disease (n=17)
Expire within 3 days (n=18)
or cystatin C was not
available after D3 (n=12)
Analyzed (n=162)
Fig. 1. Flow chart of inclusion and exclusion process for enrollment of 
patients in the study. A total of 179 patients were enrolled, and 162 pa-
tients were included in the analysis. AKI, acute kidney injury; ICU, inten-
sive care unit.
Total 179 patients with sepsis 
admitted ICU for 5 months
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changes in levels of serum creatinine and GFR, serum cystatin 
C levels were significantly higher in patients with AKI, com-
pared to non-AKI patients, on days 0, 1, 3, and 7. In the analysis 
adjusted for age, sex, APACHE II score, SOFA score, and under-
lying diseases, higher serum cystatin C levels on day 0 were sig-
nificantly associated with development of AKI [odds ratio 
(OR)=19.30; 95% CI=2.58–144.50, p=0.006] (Table 2).
Characteristics of recovery and non-recovery groups at ad-
mission to ICU (day 0) for AKI patients (n=83) are shown in Ta-
ble 3, which excludes patients who died within 3 days after ICU 
admission (n=18) or those for whom cystatin C was not mea-
sured after day 3 (n=12) from AKI patients (n=113) (Fig. 1, Table 
3). Age, gender, BMI, SOFA score, and underlying diseases were 
not significantly different between the two groups, and blood 
levels of creatinine were not significantly different between the 
two groups. Among the kidney biomarkers tested, only the lev-
els of cystatin C were higher in the non-recovery group than in 
the recovery group (p=0.003). The changes in serum creatinine, 
GFR, and cystatin C levels of the recovery and non-recovery 
groups over time are shown in Fig. 3. Serum cystatin C levels 
were significantly higher in patients in the non-recovery group, 
compared with the recovery group patients, on days 0, 1, 3, and 
7. Linear mixed model analysis showed significant differences 
in the variation in cystatin C levels over time between the re-
covery and non-recovery groups (p=0.001). After adjusting for 
age, gender, BMI, and SOFA score, the levels of serum cystatin 
C at admission to the ICU (day 0) were found to be significantly 
associated with recovery of AKI (OR=1.64; p=0.048) (Table 4).
Fig. 2. Time course of kidney markers in the AKI and non-AKI groups (n=162). Data for creatinine (A), eGFR (B), and cystatin C (C) are shown. Data 
were collected on day of admission, as well as on days 1, 3, and 7. Circle and square represent the mean value, and bar represents standard devia-
tion of the mean. *Significant differences between two groups. AKI, acute kidney injury; eGFR, estimated glomerular filtration rate.
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Table 2. Multivariate Analysis of Cystatin C for AKI Development in ICU 
Sepsis Patients (n=155, at Day 0 of ICU Admission)
Variables OR 95% CI p value
Age 1.01 0.98–1.04 0.718
Sex, F/M (%) 0.91 0.36–2.30 0.839
BMI 1.10 0.97–1.23 0.136
APACHE II score 0.99 0.90–1.11 0.977
SOFA score 1.09 0.93–1.27 0.285
Underlying diseases
Diabetes mellitus 2.08 0.62–6.98 0.238
Chronic lung disease* 0.58 0.21–1.61 0.297
Hypertension 1.39 0.51–3.82 0.518
Cystatin C 19.30 2.58–144.50 0.006
AKI, acute kidney injury; ICU, intensive care unit; OR, odds ratio; 95% CI, 
95% confidence interval; BMI, body mass index; APACHE II, Acute Physiology 
and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assess-
ment.
*Chronic lung disease includes asthma, chronic obstructive pulmonary dis-
ease, and structural lung diseases, such as bronchiectasis and interstitial 
lung disease.
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The value of cystatin C and creatinine levels measured on 
day 0 for predicting renal function was assessed with evaluation 
of receiver operating characteristic (ROC) curves, which are 
shown in Figs. 4 and 5, respectively. The ROC curve using cys-
tatin C showed a higher area under the curve (AUC) value than 
that for creatinine; however, the difference between the cystatin 
C and creatinine AUC values was not statistically significant 
(0.650 vs. 0.601; p=0.294). Similarly, an ROC curve using cys-
tatin to predict RRT showed a higher AUC value than that using 
creatinine, but again without statistical significance (0.681 vs. 
0.635; p=0.331).
In addition, the effects of age, gender, BMI, SOFA score, and 
cystatin C levels on 28-day mortality were analyzed by Cox pro-
portional hazard model (Table 5). For survival analysis, patients 
were divided into two groups according to cystatin C levels. The 
cut-off value was 1.30 mg/dL on day 0. Relative risk of mortality 
was significantly associated with cystatin C level (p=0.025). 
High cystatin C level group showed significantly worse progno-
sis than low cystatin C level group.
DISCUSSION
This study revealed an association between serum cystatin C 
levels and both AKI and renal function recovery. In multivariate 
analysis, increases in serum cystatin C levels at ICU admission 
were significantly associated with AKI, and higher levels of se-
rum cystatin C in patients with sepsis at ICU admission were 
associated with recovery of AKI among the AKI patients. The 
performance of serum cystatin C for the diagnosis of AKI and 
prediction of renal function recovery was easy to assess and 
comparably better than that of creatinine.
Sepsis remains a serious problem in critically ill patients, and 
the mortality rate in patients with sepsis is increased dramati-
cally when complicated by AKI. Therefore, accurate evaluation 
of AKI is essential in patients with sepsis. In clinical practice, 
AKI is typically diagnosed by measuring the serum creatinine 
level; however, creatinine has been shown to be a relatively in-
sensitive and late indicator of AKI.18 In a mouse model, Doi, et 
al.19 showed that sepsis reduced the production of creatinine, 
which blunted the increase in serum creatinine after sepsis, po-
tentially limiting the detection of AKI with this marker. Further-
Table 3. Clinical Characteristics of Recovery and Non-Recovery of AKI Patients at Day 0 of ICU Admission (n=83)
Variables Recovery (n=34) Non-recovery (n=49) p value
Age, yrs 64.1±14.9 61.3±16.1 0.426
Male (%) 21 (61.8) 32 (65.3) 0.741
BMI, kg/m2 23.3±3.6 23.8±4.1 0.532
Length of ICU stay, days 15.0±12.0 20.1±5.1 0.014
Disease severity
Septic shock (%) 27 (79.4) 44 (89.8) 0.186
APACHE II score 18.2±4.8 21.0±5.1 0.014
SOFA score 7.8±3.3 8.7±3.8 0.263
28-day mortality (%) 10 (29.4) 35 (71.4) <0.001
Renal replacement therapy (%) 2 (5.9) 32 (65.3) <0.001
Underlying diseases (%)
Diabetes mellitus 13 (38.2) 14 (28.6) 0.355
Chronic lung disease* 6 (17.6) 5 (10.2) 0.325
Hypertension 18 (52.9) 23 (46.9) 0.591
Heart failure 5 (14.7) 5 (10.2) 0.536
Coronary artery disease 2 (5.9) 3 (6.1) 0.964
Chronic liver disease 5 (14.7) 8 (16.3) 0.842
Clinical parameters
Hemoglobin, g/dL 10.6±2.3 9.1±1.5 0.001
Platelets, 103/mm3 184.1±145.7 204.1±181.0 0.594
Blood urea nitrogen, mg/dL 35.6±22.4 37.0±23.8 0.782
Creatine, mg/dL 2.0±1.8 2.6±2.3 0.229
eGFR, mL/min/1.73 m2 50.7±20.0 44.6±35.0 0.416
Cystatin C, mg/dL 1.3±0.7 2.1±1.5 0.003
IGF-1, μg/dL 79.3±72.8 63.0±43.8 0.394
CRP, mg/dL 17.4±11.7 17.2±13.1 0.945
AKI, acute kidney injury; BMI, body mass index; ICU, intensive care unit; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ 
Failure Assessment; eGFR, estimated glomerular filtration rate; IGF-1, insulin-like glomerular factor-1; CRP, C-reactive protein.
*Chronic lung disease includes asthma, chronic obstructive pulmonary disease, and structural lung diseases, such as bronchiectasis and interstitial lung disease.
609
Ah Young Leem, et al.
https://doi.org/10.3349/ymj.2017.58.3.604
more, Mårtensson, et al.20 found that the inflammatory re-
sponse induced by sepsis had no impact on the plasma levels 
of cystatin C during the first week in the ICU, indicating that 
cystatin C might have benefits over creatinine as a marker of 
AKI. This situation highlights the need for new biomarkers that 
could provide better measures of renal injury, especially in pa-
tients with sepsis.
In healthy subjects, serum cystatin C is excreted through 
glomerular filtration and is metabolized completely by the 
proximal tubules. It has been shown to be less influenced by 
muscular mass than serum creatinine.21 Serum cystatin C has 
been validated as a superior GFR biomarker to detect chronic 
kidney disease in several specific populations with decreased 
or abnormal muscular mass, such as in elderly and cirrhotic 
patients.22
Moreover, several studies and a subsequent meta-analysis 
demonstrated the superiority of plasma cystatin C over serum 
creatinine for the detection of minor reductions and acute 
changes in GFR.23,24 However, the superiority of serum cystatin 
C has for AKI diagnosis and prognosis has not been consis-
tent.25 Several studies conducted in critically ill patients have 
suggested the better performance of serum cystatin C for de-
tecting AKI.11,26 However, reports comparing biomarker perfor-
mance in sepsis-induced AKI are relatively scarce. Di Nardo, et 
al.27 showed that median serum cystatin C levels were signifi-
cantly increased in children with severe sepsis with AKI, com-
pared with patients without AKI, suggesting that cystatin C 
could be a more specific biomarker of AKI in children with se-
vere sepsis. Similarly, in the present study, increases in serum 
cystatin C levels at ICU admission were significantly associated 
with AKI in an adjusted analysis for age, sex, SOFA score, and 
underlying diseases. However, there is a limitation in compar-
ing the results between these two studies, because only adults 
were enrolled in our study. Dai, et al.28 found that the plasma 
cystatin C levels were significantly associated with AKI devel-
opment in patients with sepsis, even after adjustment for con-
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Fig. 3. Time course of kidney markers in the recovery and non-recovery groups (n = 83). Data for creatinine (A), eGFR (B), and cystatin C (C) are 
shown. Data were collected on day of admission, as well as on days 1, 3, and 7. Circle and square represent the mean value, and bar represents 
standard deviation of the mean. *Significant differences between two groups. eGFR, estimated glomerular filtration rate.
Table 4. Multivariate Analysis of Cystatin C for Non-Recovery of AKI in 
Sepsis-Induced AKI Patients (n=83, at Admission, Day 0)
Variables OR 95% CI p value
Age 0.99 0.96–1.02 0.537
Sex, F/M (%) 0.69 0.25–1.93 0.479
BMI 0.99 0.87–1.12 0.819
APACHE II score 1.10 0.99–1.22 0.064
Cystatin C 1.64 1.00–2.68 0.048
AKI, acute kidney injury; OR, odds ratio; 95% CI, 95% confidence interval; 
BMI, body mass index; APACHE II, Acute Physiology and Chronic Health Eval-
uation II.
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founders, thus supporting the results of our study.
Although serum cystatin C has long been recognized as a 
good biomarker of renal injury and performs better than the 
conventional biomarkers, such as creatinine and nitrogen urea, 
in reflecting renal function,23,29 the association between serum 
cystatin C and prediction of renal function recovery in sepsis-
induced AKI has not been well established. Perianayagam, et 
al.30 measured serum cystatin C in 200 patients with AKI, 83 of 
whom died or underwent RRT. They found that the serum cys-
tatin C level performed just as well as the serum creatinine lev-
el, serum urea nitrogen level, and urine output in predicting di-
alysis requirement or in-hospital death. Since hospitalized 
adult patients who were not critically ill patients were also en-
rolled in the study, it is difficult to directly compare their results 
to those of the present study. Royakkers, et al.31 reported that 
serum cystatin C and urine cystatin C were poor biomarkers for 
the prediction of AKI and stated the need for RRT in a prospec-
tive multi-center cohort study of ICU patients. However, their 
study included heterogeneous AKI patients in the ICU (i.e., not 
only sepsis-induced AKI), and only 39.1% of the patients had 
septic shock, compared to 85.8% of the patients, in the present 
study. This difference in disease severity between the cohorts 
makes it difficult to directly compare the results between stud-
ies. In a cohort study of ICU patients, plasma cystatin C predict-
ed sustained AKI and death or RRT and performed similarly to 
plasma creatinine as a biomarker.7 These results are similar to 
ours; however, only 18.2% of the patients in that cohort had 
sepsis. Furthermore, the results of these previous studies may 
be limited, owing to the relatively low event rates, such as death 
or RRT. In most previous studies evaluating the role of serum 
cystatin C in AKI patients, not only sepsis-induced AKI patients 
were enrolled, and the primary outcome was mainly the com-
posite of dialysis therapy requirement or in-hospital death. In 
contrast, in our study, only sepsis-induced AKI patients were 
enrolled, and the primary outcome of interest was renal func-
tion recovery within 1 month.
Nevertheless, our study has some limitations. First, this pro-
spective observational study was a single-center study with a 
relatively small sample size. However, serial follow up for bio-
markers for kidney injury was carried out to potentially com-
pensate for this weakness. Second, other new biomarkers, such 
as neutrophil gelatinase-associated lipocalin, were not ana-
lyzed. Third, although serum cystatin C level is less influenced 
by age, sex, and muscle mass, compared with serum creati-
nine level, it may still be affected by other unmeasured vari-
Fig. 4. Receiver operator characteristic (ROC) curves of creatinine and 
cystatin C levels on day 0 to predict renal function recovery. ROC curve 
using cystatin C showed a higher area under the curve (AUC) value than 
that using creatinine; however, the difference between cystatin C and 
creatinine AUC values was not statistically significant.
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Fig. 5. Receiver operator characteristic (ROC) curves of creatinine and 
cystatin C levels on day 0 to predict renal replacement therapy. ROC 
curve using cystatin C showed a higher area under the curve value than 
the one using creatinine; however, the difference was not statistical 
significant.
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Table 5. Cox Proportional Models of Survival in Sepsis-Induced AKI Pa-
tients (n=83, at Admission, Day 0)
Variables HR 95% CI p value
Age 1.01 0.98–1.03 0.798
Sex, F/M (%) 0.73 0.32–1.66 0.449
BMI 1.07 0.97–1.19 0.168
SOFA score 1.10 0.99–1.23 0.084
Cystatin C 0.025
Low
High 2.70 1.13–6.43 0.025
AKI, acute kidney injury; HR, hazard ratio; 95% CI, 95% confidence interval; 
BMI, body mass index; SOFA, Sequential Organ Failure Assessment.
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ables, such as levels of glucocorticoids,32 thyroid hormones,33 
and insulin.34 However, glucocorticoids and insulin were used 
in all patients according to the same protocol, thereby minimiz-
ing these potential influences. Third, this study enrolled sepsis-
AKI and sepsis-no-AKI patients, while not screening no-AKI 
and no-sepsis-AKI patients. Fourth, when AKI occurred within 
3 days after ICU admission, patients were classified as AKI 
group. As a result, predictive value of cystatin C may have been 
limited.
In conclusion, this study showed that the serum cystatin C 
level can be associated with the development and worsening of 
AKI in ICU patients with sepsis. Larger and multi-center studies 
appear to be justified to confirm these results and to establish 
serum cystatin C as a useful biomarker for early diagnosis and 
prognosis of AKI.
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